Skip to main content

Dr. Patni is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Patni's full profile

Already have an account?

  • Office

    66 Lisa Dr
    Chatham, NJ 07928
    Phone+1 973-701-1084

Summary

  • I am a cardiologist, who has been focused on clinical drug development in the pharmaceutical / biotechnology industry. To date, I have been involved in approximately 20 drug development programs, including dofetilide, quinapril, amlodipine, sildenafil, aliskiren, and macitentan. My approach has been partnering with academia and the FDA to design and execute pragmatic yet robust clinical trials to ultimately inform the creation of product labels, that are truthful and clinically relevant. In this way, the product label can inform responsible and appropriate utilization by the prescribing physician.

Education & Training

  • Montefiore Medical Center/Albert Einstein College of Medicine (Montefiore)
    Montefiore Medical Center/Albert Einstein College of Medicine (Montefiore)Fellowship, Cardiovascular Disease, 1998 - 2000
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1995 - 1998
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 1994 - 1995
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1994

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2026
  • NJ State Medical License
    NJ State Medical License 2009 - 2025
  • NY State Medical License
    NY State Medical License 1996 - 2025
  • PA State Medical License
    PA State Medical License 1997 - 1998

Publications & Presentations

PubMed

Press Mentions

  • Portola Pharmaceuticals Announces Results Demonstrating Andexxa® Was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
    Portola Pharmaceuticals Announces Results Demonstrating Andexxa® Was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related BleedsMarch 16th, 2020
  • Portola Pharmaceuticals Unveils Data on Andexxa in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
    Portola Pharmaceuticals Unveils Data on Andexxa in Patients with Multiple Types of Factor Xa Inhibitor-Related BleedsMarch 16th, 2020
  • New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
    New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa InhibitorsMarch 5th, 2020
  • Join now to see all